Linperlisib Combination With Cyclophosphamide, Prednisone, and Thalidomide (CPT) in R/R NHL

Must have received: CD20 monoclonal antibody — second-line or later

FL patients: Should be relapsed after second-line or more systemic therapy (CD20 monoclonal antibody and at least one alkylating agent, including but not limited to bendamustine, fludarabine, cyclophosphamide, isocyclophosphamide, etc.)

Must have received: alkylating agent (bendamustine, fludarabine, cyclophosphamide, isocyclophosphamide) — second-line or later

FL patients: Should be relapsed after second-line or more systemic therapy (CD20 monoclonal antibody and at least one alkylating agent, including but not limited to bendamustine, fludarabine, cyclophosphamide, isocyclophosphamide, etc.)

Must have received: systemic therapy — at least one prior line

PTCL patients: Have previously received at least one-line systemic treatment, have disease progression during or after the most recent treatment, or confirmed no objective response with adequate treatment

Must have received: CD30-targeted therapy

patients with ALCL must have previously received CD30-targeted therapy or be ineligible for CD30-targeted therapy

Must have received: systemic therapy — at least one prior line

NK/TCL patients: Have previously received at least one line systemic treatment, have disease progression during or after the most recent treatment, or have confirmed no objective response with adequate treatment

Must have received: Pegaspargase or L-Pegaspargase (Pegaspargase, L-Pegaspargase)

NK/TCL patients: Have previously received a regimen containing Pegaspargase or L-Pegaspargase

Must have received: BTK inhibitor — first-line or above

CLL patients: Patients with resistance or intolerance following prior first-line or above therapy (regiments containing BTK inhibitors or BCL-2 inhibitors)

Must have received: BCL-2 inhibitor — first-line or above

CLL patients: Patients with resistance or intolerance following prior first-line or above therapy (regiments containing BTK inhibitors or BCL-2 inhibitors)

Must have received: CD20 monoclonal antibody — at least two-line systemic therapy

MZL patients: Should have previously received at least two-line systemic therapy containing CD20 monoclonal antibodies and have not achieved at least partial response (PR) after recent systemic therapy, or have confirmed disease progression after treatment, and investigators judge that effective and standard treatment options are lacking

Must have received: immunotherapy or chemical immunotherapy containing anti-CD20 monoclonal antibody — first-line or above

MCL patients: Previous second-line or higher treatment regimen including: at least first-line immunotherapy or chemical immunotherapy containing anti-CD20 monoclonal antibody; Or anti-CD20 mab combined with BTK inhibitors

Must have received: BTK inhibitor

MCL patients: have been treated with at least one appropriate BTK inhibitor and BCL-2 inhibitor (monotherapy or in combination with other antineoplastic agents)

Must have received: BCL-2 inhibitor

MCL patients: have been treated with at least one appropriate BTK inhibitor and BCL-2 inhibitor (monotherapy or in combination with other antineoplastic agents)

Cannot have received: PI3K inhibitor

Had been progressed on PI3K inhibitor before enrollment

Cannot have received: any anti-tumor therapy

Exception: washout period at least 28 days or five half-life of the drug, whichever was shorter

Any other anti-tumor therapy within 4 weeks

Cannot have received: autologous hematopoietic stem cell transplantation

Exception: allowed if >90 days prior to first dose

Received autologous hematopoietic stem cell transplantation within 90 days prior to the first dose of study treatment